We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Perphenazine Attenuates the Pro-Inflammatory Responses in Mouse Models of Th2-Type Allergic Dermatitis.
- Authors
Heo, Min-Jeong; Choi, Soo Young; Lee, Chanmi; Choi, Yeong Min; An, In-sook; Bae, Seunghee; An, Sungkwan; Jung, Jin Hyuk
- Abstract
Developing dermatitis therapeutics has been faced with challenges including adverse effects of topical steroid and high cost of new developing drugs. Here, we found the expression levels of dopamine receptor D2 is higher in skin biopsies of dermatitis patients and an oxazolone-induced animal model of dermatitis. We used perphenazine, an FDA-approved dopamine receptor antagonist to determine the therapeutic effect. Two different animal models including 12-o-tetradecanoylphorbol-13-acetate (TPA) and oxazolone (OXA)-induced dermatitis were employed. TPA and OXA-mediated ear swelling was attenuated by perphenazine. Moreover, perphenazine inhibited infiltrated mast cells into lesion area. We found levels of serum IgE, histamine and cytokines are decreased in mice cotreated with perphenazine and OXA compared to OXA-treated mice. Overall, this is a first study showing that the FDA-approved, anti-psychotic drug, perphenazine, alleviates animal models of dermatitis.
- Subjects
UNITED States. Food &; Drug Administration; CONTACT dermatitis; DOPAMINE receptors; TREATMENT effectiveness; DOPAMINE antagonists; MAST cells; IMMUNOGLOBULIN E; SKIN biopsy
- Publication
International Journal of Molecular Sciences, 2020, Vol 21, Issue 9, p3241
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms21093241